Cancer related antigen
AssigneeThe John Hopkins University
InventorsFrancis P. Kuhajda, Gary R. Pasternack
Life of this patent
Estimating the term…
Abstract
A method of determining the prognosis of a solid tumor is provided, in which a sample from a patient bearing a tumor is assayed for the presence of a protein which is immunologically cross-reactive with the hpr gene product, but not with haptoglobin 1 or haptoglobin 2. Also provided is a method for preparing antibodies specific for this diagnostic marker which correlates with early relapse and metastasis of breast and other cancers. The marker can be detected using immunological methods employing antibodies specific for Hpr protein and not cross-reactive with haptoglobins 1 or 2.
Claims10
A nucleic acid molecule produced by recombinant methods, containing a nucleotide sequence comprising inserts from clones pFAS 1.6, pFAS3.0, pFAS2.2 and pFAS4.6 deposited under ATCC accession Nos. 75643, 75645, 75644 and 75646, respectively, assembled in accordance with a Clone Map shown in FIG. 12D.
A nucleic acid molecule produced by recombinant methods, wherein said nucleic acid molecule encodes the amino acid sequence of SEQ ID NO:10.
An isolated nucleic acid probe comprising at least 20 contiguous nucleotides selected from or complementary to one strand of a double stranded nucleic acid molecule according to SEQ ID NO:9.
An isolated nucleic acid probe which specifically hybridizes to a single band which comprises a nucleic acid molecule comprising SEQ ID NO:9 but not to other mRNA molecules from ZR-75-1 breast cancer cells on Northern blots.
A pair of nucleic acid primers comprising at least 10 contiguous nucleotides selected from or complementary to a sequence of SEQ ID NO:9, wherein nucleic acid amplification using the pair of nucleic acid primers will produce an amplified nucleic acid comprising at least a portion of the sequence of SEQ ID NO:9.
Dependencies are inferred from the claim text.